Literature DB >> 7371799

Suppression of cytophilic antibody ('arming' factor) in the sera of patients with prostatic cancer by human seminal plasma.

R A Bhatti, R J Ablin, S Zamora, E Totonchi, I M Bush, P D Guinan.   

Abstract

The 'arming' of normal peripheral blood leukocytes (PBL) by cytophilic antibody in the sera of prostatic cancer patients is suppressed by pretreatment of PBL with normal human seminal plasma (HuSPl). Suppression of cytophilic antibody by HuSPl extends the spectrum of immunologic reactions on which SPl has an immunosuppressive effect and may provide further insight into the possible role of SPl in the natural history of prostatic cancer.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7371799     DOI： 10.1007/bf01952320

Source DB:  PubMed          Journal:  Experientia        ISSN： 0014-4754


  5 in total

Review 1.  Occult carcinoma of the prostate: an oversight of immune surveillance--a working hypothesis.

Authors:  R F Gittes; D L McCullough
Journal:  J Urol       Date:  1974-08       Impact factor: 7.450

2.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

3.  Cell-mediated antitumor immunity in breast cancer patients evaluated by antigen-induced leukocyte adherence inhibition in test tubes.

Authors:  N Grosser; D M Thomson
Journal:  Cancer Res       Date:  1975-09       Impact factor: 12.701

4.  Arming of normal leukocytes with sera from patients with adenocarcinoma of the prostate.

Authors:  R A Bhatti; R J Ablin; W Condoulis; P D Guinan
Journal:  Cancer Res       Date:  1979-09       Impact factor: 12.701

5.  Effect of human seminal plasma on tumour-associated immunity in prostatic cancer. A preliminary report.

Authors:  R J Ablin; R A Bhatti; P D Guinan; I M Bush
Journal:  Experientia       Date:  1979-11-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.